US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SVB Financial Group

0.0060

0.0000

Volume:- -

Turnover:- -

Market Cap:355.65K

PE:0.00

High:0.0060

Open:0.0060

Low:0.0060

Close:0.0060

Loading ...

Overview Company News Filings

BUZZ-10x Genomics falls on disappointing 2025 sales forecast

BUZZ-Owens & Minor falls as prelim Q4 revenue miss estimates

BUZZ-Street View: FDA nod for Vertex's oral non-opioid painkiller 'the start of something big'

BUZZ-Walgreens falls after suspending quarterly dividend

EUROPE RESEARCH ROUNDUP-Admiral, Dowlais Group, Tullow Oil

BUZZ-Wellington-backed Beta Bionics valued at $944 mln in cracking Nasdaq debut

Beta Bionics raises $204 mln in upsized US IPO

Beta Bionics targets $695 mln valuation in upsized US IPO

BUZZ-Leerink Partners lowers PT on drugmaker Regeneron

BUZZ-Walgreens falls after report says deal with Sycamore 'mostly dead'

Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO

U.S. RESEARCH ROUNDUP-DTE Energy, Evergy, Exelon

Beta Bionics targets up to $616 mln valuation in US IPO

BUZZ-Warner Bros Discovery rises after MoffettNathanson upgrades to 'buy'

BUZZ-Brokerages downgrade Intra-Cellular after J&J deal

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SIVBQ/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SIVBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SIVBQ\",,,,,undefined,":{"symbol":"SIVBQ","market":"US","secType":"STK","nameCN":"SVB Financial Group","latestPrice":0.006,"timestamp":1753473600000,"preClose":0.006,"halted":0,"volume":0,"delay":15,"floatShares":53990110,"shares":59274992,"eps":25.35,"marketStatus":"Market Closed","change":0,"latestTime":"07-25 16:00:00 EDT Delay","open":0.006,"high":0.006,"low":0.006,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":25.35,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":7,"adr":0,"exchange":"EXPERT","adjPreClose":0.006,"volumeRatio":0.05575453697142266},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SIVBQ\",,,,,undefined,":{"symbol":"SIVBQ","floatShares":53990110,"roa":"0.76%","roe":"9.78%","lyrEps":25.581907,"volumeRatio":0.05575453697142266,"shares":59274992,"dividePrice":0,"high":0.006,"amplitude":0,"preClose":0.006,"low":0.006,"week52Low":0.0011,"pbRate":"0.00","psRate":"0.00","week52High":0.1,"institutionHeld":0,"latestPrice":0.006,"eps":25.35,"divideRate":0,"volume":0,"delay":15,"ttmEps":25.35,"open":0.006,"prevYearClose":0.006,"prevWeekClose":0.006,"prevMonthClose":0.006,"prevQuarterClose":0.006,"fiveDayClose":0.006,"twentyDayClose":0.006,"sixtyDayClose":0.006},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SIVBQ\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2511543232","title":"BUZZ-10x Genomics falls on disappointing 2025 sales forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2511543232","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511543232?lang=en_us&edition=fundamental","pubTime":"2025-02-13 19:28","pubTimestamp":1739446125,"startTime":"0","endTime":"0","summary":"BUZZ-10x Genomics falls on disappointing 2025 sales forecast** Shares of genetic research equipment maker 10x Genomics TXG.O down 2.7% to $11.68 premarket** Co sees 2025 revenue in the range of $610 million to $630 million, with midpoint below average of analyst's estimates of $622 million - LSEG data ** Posts Q4 loss of 40 cents per share compared to analyst's estimates of 29 cents per share** \"Despite the current uncertainty within U.S. academic research, we continue to have strong conviction in the large opportunity ahead\" - CEO Serge Saxonov. that sales of companies such as TXG and Quanterix QTRX.O would be hit in Q1, as research centers and medical schools get cautious about purchasing equipment amid expected cost cuts of $4 billion at the National Institutes of Health","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nL4N3P40YP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIVBQ","QTRX","TXG"],"gpt_icon":0},{"id":"2508148150","title":"BUZZ-Owens & Minor falls as prelim Q4 revenue miss estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2508148150","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508148150?lang=en_us&edition=fundamental","pubTime":"2025-02-03 21:23","pubTimestamp":1738588997,"startTime":"0","endTime":"0","summary":"BUZZ-Owens & Minor falls as prelim Q4 revenue miss estimates** Shares of medical supplies distributor Owens & Minor OMI.N fall 1.9% to $13.98 premarket ** Co reports preliminary Q4 revenue of $2.67 bln to $2.70 bln, below analysts' estimates of $2.73 bln - LSEG-compiled data** Reports prelim Q4 adj. profit of 52 cents to 55 cents per share, compared with estimates of 53 cents per share ** Reports prelim Q4 adj. core earnings of $135 mln to $140 mln vs estimates of $155.51 mln** \"Today's announcement will likely create more questions about underlying margins given the adjusted EBITDA underperformance in the quarter \" - brokerage Leerink Partners** Co also says it is commencing a process to raise additional debt to finance its Rotech acquisition** Co in July said it has agreed to buy medical equipment firm Rotech Healthcare for $1.36 billion in cash to expand its presence in home-based care** Stock had fallen 32.2% in 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nL4N3OU10U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIVBQ","OMI"],"gpt_icon":0},{"id":"2507597299","title":"BUZZ-Street View: FDA nod for Vertex's oral non-opioid painkiller 'the start of something big'","url":"https://stock-news.laohu8.com/highlight/detail?id=2507597299","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507597299?lang=en_us&edition=fundamental","pubTime":"2025-01-31 19:42","pubTimestamp":1738323723,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: FDA nod for Vertex's oral non-opioid painkiller 'the start of something big'** The U.S. Food and Drug Administration on Thursday approved Vertex Pharmaceuticals' VRTX.O drug, branded as Journavx, to treat acute pain, offering a first-of-its-kind alternative to addictive opioid painkillers that have fueled a national crisis** Shares up 7.39% to $470.8 premarketPRICING NOT HIGH AS FEARED** BMO Capital Markets  says approval in acute pain sets stage for VRTX's next leg of growth** Truist Securities  says price tag of Journavx is certainly higher than generic opioids, but not as high as feared** Leerink Partners  notes the published drug labeling as a best-case scenario, pricing is roughly in line with its expectations** TD Cowen  suspects it may take time for Journavx's launch to gain momentum  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nL3N3OR0P8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","LU1430594728.SGD","BK4532","BK4207","LU1585245621.USD","BK4139","LU0256863811.USD","LU0320765992.SGD","LU0061475181.USD","IE00B4R5TH58.HKD","BK4589","LU2324357040.USD","SIVBQ","IE00B19Z3581.USD","BK4533","LU0058720904.USD","LU2362541273.HKD","LU2456880835.USD","LU0823416689.USD","IE0002270589.USD","LU2417539215.USD","LU0079474960.USD","BK4211","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE0009355771.USD","LU2362541513.USD","LU1035775433.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","IE00B894F039.SGD","BK4567","IE00B19Z9P08.USD","LU1069344957.HKD","IE00BJJMRZ35.SGD","LU0417517546.SGD","IE00BZ9MQY76.HKD","LU1093756325.SGD","LU0109394709.USD","LU1093756168.USD","LU2462157665.USD","LU0889565916.HKD","BK4585","IE00B19Z9Z06.USD","LU2362540622.SGD","LU2236285917.USD","VRTX","BK4588","LU0234570918.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2507958181","title":"BUZZ-Walgreens falls after suspending quarterly dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2507958181","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507958181?lang=en_us&edition=fundamental","pubTime":"2025-01-31 17:55","pubTimestamp":1738317307,"startTime":"0","endTime":"0","summary":"BUZZ-Walgreens falls after suspending quarterly dividend** Shares of pharmacy chain operator Walgreens Boots Alliance WBA.O fall 10.03% to $10.31 premarket** Co said on Thursday its board of directors is suspending cash dividend historically paid to stockholders on quarterly basis, as management continues to evaluate and refine its capital allocation policy consistent with its turnaround efforts** This change in capital allocation is aimed at strengthening WBA's balance sheet by reducing debt over time and improving free cash flow, co said** Brokerage Leerink Partners sees it as right move for WBA's ability to reboot business** Evercore ISI says cash can go towards store closure costs, debt repayment and/or other strategic initiatives** Stock fell ~64% in 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nL3N3OR0JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505868.SGD","BK4589","BK4585","BK4128","BK4207","BK4588","LU0321505439.SGD","SIVBQ","BK4211","WBA"],"gpt_icon":0},{"id":"2507939646","title":"EUROPE RESEARCH ROUNDUP-Admiral, Dowlais Group, Tullow Oil","url":"https://stock-news.laohu8.com/highlight/detail?id=2507939646","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507939646?lang=en_us&edition=fundamental","pubTime":"2025-01-31 15:17","pubTimestamp":1738307861,"startTime":"0","endTime":"0","summary":"EUROPE RESEARCH ROUNDUP-Admiral, Dowlais Group, Tullow Oil Jan 31 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Admiral, Dowlais Grou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nL3N3OR0FL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIVBQ","LU1223082196.USD","BK4207","BK5159","BK5065","LU0055631609.USD","DWL.UK","BK4211","SQZ.UK","LU0498741114.HKD","LU0368265764.SGD","TLW.UK","LU0498741890.SGD","BK4588","BK5119","EDV.UK","BK4585","LU1223083913.SGD","BK4589","LU0496367417.USD"],"gpt_icon":0},{"id":"2507267930","title":"BUZZ-Wellington-backed Beta Bionics valued at $944 mln in cracking Nasdaq debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2507267930","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507267930?lang=en_us&edition=fundamental","pubTime":"2025-01-31 01:54","pubTimestamp":1738259663,"startTime":"0","endTime":"0","summary":"BUZZ-Wellington-backed Beta Bionics valued at $944 mln in cracking Nasdaq debut** Shares of insulin delivery device maker Beta Bionics BBNX.O jump as much as 41.2% in their Nasdaq debut** Stock opens for trading at $22, valuing the Irvine, California-based company at $943.6 mln** BBNX sold 12 mln shares, 60% more than initially offered, at the top end of its marketed range of $16 and $17 to raise $204 mln** IPO was twice upsized and follows medical device maker CeriBell's CBLL.O strong debut last year, underscoring a gradual recovery in medtech listings** BBNX's strong show comes in the aftermath of underwhelming debuts by major IPO candidates including LNG exporter Venture Global VG.N and pork producer Smithfield Foods SFD.O ** BofA Securities, Piper Sandler, Leerink Partners, Stifel and Lake Street were the underwriters for the offering    ** Asset manager Wellington Management, an existing Beta shareholder, had agreed to purchase $17 million worth of the company's shares in a concur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nL3N3OQ1R4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683348.USD","SGXZ90724238.SGD","IE00BLSP4239.USD","LU1791807156.HKD","LU0321505868.SGD","LU2133065610.SGD","BK4585","BK4589","BK4559","LU2129689431.USD","SG9999002950.SGD","BK1543","LU0320765489.SGD","BK1521","LU1280957306.USD","LU1718418525.SGD","BK4581","SF","BK4211","LU1162221912.USD","LU1496350502.SGD","LU1074936037.SGD","LU1166156734.SGD","IE00BBT3K403.USD","PIPR","IE00B1BXHZ80.USD","LU1267930227.SGD","LU1880398554.USD","LU0149725797.USD","LU0868494617.USD","SIVBQ","LU1668664300.SGD","LU0053666078.USD","LU0234572021.USD","LU1201861165.SGD","IE00BFXG1179.USD","00288","BAC","LU0130518102.USD","LU0130102774.USD","LU2129689514.USD","LU0306807586.USD","SG9999001051.SGD","LU0321505439.SGD","BK4534","BK4504","IE00BZ1G4Q59.USD","IE00BLSP4452.SGD","LU0980610538.SGD","LU0256863902.USD"],"gpt_icon":0},{"id":"2507692758","title":"Beta Bionics raises $204 mln in upsized US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2507692758","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507692758?lang=en_us&edition=fundamental","pubTime":"2025-01-30 12:07","pubTimestamp":1738210036,"startTime":"0","endTime":"0","summary":"Jan 29  - Insulin delivery device maker Beta Bionics said on Wednesday it raised $204 million in its initial public offering  at a valuation of about $700 million.The U.S.-based company said it priced its IPO at $17 per share, the upper-end of its forecasted range of $16 to $17 per share.The size of the offering was raised to 12 million shares from 10 million shares, the company said.Beta bucks the recent trend where major IPO candidates such as LNG exporter Venture Global VG.N and pork producer Smithfield Foods SFD.O had to lower their valuation targets.Beta's shares will start trading on the Nasdaq under the symbol \"BBNX\" on Thursday.BofA Securities, Piper Sandler, Leerink Partners, Stifel and Lake Street are the underwriters for the offering.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nL3N3OQ07F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863811.USD","SIVBQ","VG","BK1237","LU0170899867.USD","LU2129689514.USD","00288","IE00BLSP4239.USD","LU0130102774.USD","LU0052756011.USD","LU1166156734.SGD","PIPR","LU1496350171.SGD","SF","LU0130103400.USD","LU1363072403.SGD","LU0321505439.SGD","SG9999001226.SGD","BAC","IE00B19Z3B42.SGD","BK4585","LU0683600562.USD","LU1668664300.SGD","SGXZ90724238.SGD","BK4127","BK4553","LU1718418525.SGD","IE00BKVL7J92.USD","LU0648000940.SGD","BBNX","BK4588","LU0980610538.SGD","LU1162221912.USD","SG9999002950.SGD","SG9999001051.SGD","LU2133065610.SGD","LU2129689605.HKD","LU0274383008.USD","LU1201861249.SGD","SFD","LU1880398471.USD","LU1883839398.USD","LU0320765646.SGD","LU0321505868.SGD","LU0287142896.SGD","BK1603","BK4211","LU1280957306.USD","LU1496350502.SGD","IE00BBT3K403.USD"],"gpt_icon":0},{"id":"2506351292","title":"Beta Bionics targets $695 mln valuation in upsized US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2506351292","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506351292?lang=en_us&edition=fundamental","pubTime":"2025-01-28 23:01","pubTimestamp":1738076483,"startTime":"0","endTime":"0","summary":"Jan 28  - Beta Bionics is targeting a valuation of up to $695 million in an upsized initial public offering, the insulin delivery device maker said on Tuesday.The company will aim to raise up to $170 million through a sale of 10 million shares priced between $16 and $17 each. It was earlier targeting proceeds of $120 million.Beta bucks the recent trend where major IPO candidates such as LNG exporter Venture Global VG.N and pork producer Smithfield Foods had to lower their valuation targets. Analysts have said that the demand for new share sales remains strong but new entrants will need to aim for more realistic valuations. Wellington Management, a Beta shareholder, has agreed to purchase $17 million worth of the company's shares in a concurrent private placement at the IPO price.Beta's shares will start trading on the Nasdaq under the symbol \"BBNX\". BofA Securities, Piper Sandler, Leerink Partners, Stifel and Lake Street are the underwriters for the offering.       ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nL3N3OO14I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","LU2129689514.USD","IE00BZ1G4Q59.USD","LU0541501648.USD","LU1791807156.HKD","LU1718418525.SGD","BK4585","LU0648000940.SGD","BK4207","LU0130103400.USD","LU0868494617.USD","BK4589","LU1074936037.SGD","LU1201861249.SGD","LU1880398471.USD","SG9999001069.SGD","LU0321505868.SGD","LU0130518102.USD","SG9999002950.SGD","SIVBQ","BK4581","BK1603","SF","BK4211","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU1280957306.USD","IE00BBT3K403.USD","PIPR","BAC","LU0702159699.USD","SG9999001226.SGD","LU1496350502.SGD","LU0541502299.USD","LU0106831901.USD","SGXZ90724238.SGD","IE00B1BXHZ80.USD","LU0173614495.USD","LU1894683348.USD","BK4127","LU0170899867.USD","00288","LU0648001328.SGD","LU1668664300.SGD","IE00B7SZLL34.SGD","LU0477156797.USD","LU0321505439.SGD","BK1521","LU0640476718.USD","BK4553"],"gpt_icon":0},{"id":"2506515247","title":"BUZZ-Leerink Partners lowers PT on drugmaker Regeneron","url":"https://stock-news.laohu8.com/highlight/detail?id=2506515247","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506515247?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:39","pubTimestamp":1738071554,"startTime":"0","endTime":"0","summary":"BUZZ-Leerink Partners lowers PT on drugmaker Regeneron ** Leerink Partners lowers PT on drugmaker Regeneron Pharmaceuticals REGN.O to $762 from $880; maintains rating of \"market perform\" ** Brokerage says it lowered 2025 EPS estimates to $40.96 from $44.01 due to REGN's eye drug Eylea franchise pressures and investment spending requirements; analysts on average estimate 2025 EPS to be $44.76, according to data compiled by LSEG** Leerink notes REGN may face potential pricing pressure on Eylea HD in international markets outside of U.S.** Last year, REGN reported Q3 sales of $392 mln for higher dose version of Eylea, missing expectations of $417 mln** Brokerage says it expects REGN to defend its Eylea 2mg market share against Amgen's AMGN.O biosimilar, Pavblu** Expects U.S. Eylea sales to be constrained due to lack of pre-filled syringe, monthly dosing and RVO indication** REGN fell 21.3% in 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nL3N3OO0U0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1571399168.USD","IE0002141913.USD","LU0889565916.HKD","BK4139","IE0009355771.USD","LU2089984988.USD","LU0868494617.USD","REGN","LU1917777945.USD","LU2362541513.USD","IE00B4R5TH58.HKD","LU2112291526.USD","SG9999001440.SGD","SIVBQ","LU2242646821.SGD","LU2106854487.HKD","LU0289739699.SGD","LU0122379950.USD","LU2362540622.SGD","BK4588","LU0058720904.USD","IE00BJT1NW94.SGD","BK4207","BK4533","LU1061106388.HKD","BK4566","LU0053666078.USD","BK4534","LU0114720955.EUR","LU1974910355.USD","BK4581","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU2468319806.SGD","BK4589","LU0320765992.SGD","LU0109394709.USD","LU0823416689.USD","BK4599","AMGN","LU2237438978.USD","BK4211","LU2362541273.HKD","IE00B2B36J28.USD","LU2242652126.USD","IE00BFTCPJ56.SGD","LU2023250504.SGD","LU1983299246.USD"],"gpt_icon":0},{"id":"2506304085","title":"BUZZ-Walgreens falls after report says deal with Sycamore 'mostly dead'","url":"https://stock-news.laohu8.com/highlight/detail?id=2506304085","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506304085?lang=en_us&edition=fundamental","pubTime":"2025-01-28 00:33","pubTimestamp":1737995612,"startTime":"0","endTime":"0","summary":"BUZZ-Walgreens falls after report says deal with Sycamore 'mostly dead'** Shares of pharmacy chain Walgreens Boots Alliance WBA.O fall 6.7% to $11.08** The deal between private equity firm Sycamore Partners and WBA is \"mostly dead\", CNBC journalist David Faber commented live on air, citing sources familiar with the matter** WBA was looking to sell itself to Sycamore Partners and had also reached out to other potential buyers, according to media outlets** Walgreens did not immediately respond to a request for comment** The potential deal was a \"longshot given the size of the deal, financing considerations, and challenges finding a robust expected return\" - Leerink Partners ** WBA beat analysts' expectations for Q1 profit earlier this month and indicated that its restructuring was taking hold** \"Keeping that momentum will be the key driver to rebuild sentiment, although we would not be surprised to see further stock volatility as deal speculation dies down,\" said Leerink analysts** Up to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nL3N3ON14M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505868.SGD","BK4207","LU0321505439.SGD","BK4589","BK4211","BK4588","WBA","BK4128","SIVBQ","BK4585"],"gpt_icon":0},{"id":"2506373131","title":"Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2506373131","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506373131?lang=en_us&edition=fundamental","pubTime":"2025-01-27 19:35","pubTimestamp":1737977707,"startTime":"0","endTime":"0","summary":"UPDATE 3-Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPOMaze seeks as much as $133 mln in New York IPOBackers include Alphabet's GV and Third Rock VenturesBiotech IPOs set for ramp up in coming weeksAdds analyst comment in paragraph 4, background on Maze's Pompe disease therapy in paragraph 9By Arasu Kannagi Basil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nL3N3ON0MH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIVBQ","BK4207","BK4585","BK4211","BK4588","BK4589"],"gpt_icon":0},{"id":"2505059452","title":"U.S. RESEARCH ROUNDUP-DTE Energy, Evergy, Exelon","url":"https://stock-news.laohu8.com/highlight/detail?id=2505059452","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505059452?lang=en_us&edition=fundamental","pubTime":"2025-01-23 14:44","pubTimestamp":1737614698,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-DTE Energy, Evergy, Exelon Jan 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including DTE Energy, Ever","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nL3N3OJ0G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B42XCP33.USD","LU0882574055.USD","IE00BFMHRM44.USD","LU1914381329.SGD","FITB","WTFC","ELV","LU0345770308.USD","LU2362540622.SGD","CMA","LU2264538146.SGD","DECK","SEE","LU1280957306.USD","SIVBQ","RVLV","TRV","BKU","TDY","FLO","BK4534","LU1670628061.USD","MODV","LU0251142724.SGD","BK4585","LU0211331839.USD","APH","BK4127","CROX","TXT","ABT","DAR","IE00BVYPNV92.GBP","ALLY","PNFP","GEV","SAM","LU0237698245.USD","UCB","CBSH","PG","MC","LU1066051498.USD","BOOT","HAL","LU1559883803.SGD","VIRT"],"gpt_icon":1},{"id":"2505455743","title":"Beta Bionics targets up to $616 mln valuation in US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2505455743","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505455743?lang=en_us&edition=fundamental","pubTime":"2025-01-22 19:48","pubTimestamp":1737546489,"startTime":"0","endTime":"0","summary":"UPDATE 1-Beta Bionics targets up to $616 mln valuation in US IPOAdds details throughout","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nL3N3OI0UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","IE00BBT3K403.USD","LU2129689514.USD","LU0306807586.USD","LU0256863811.USD","BK4585","SF","LU1880398471.USD","IE00B19Z3B42.SGD","LU1267930227.SGD","IE00B19Z3581.USD","BAC","LU0149725797.USD","LU0320765489.SGD","BK4553","BK4082","BK4559","CBLL","LU0971096721.USD","LU0130103400.USD","LU1894683264.USD","LU0128525689.USD","LU0321505868.SGD","LU0208291251.USD","LU0321505439.SGD","LU0130518102.USD","LU1718418525.SGD","BK4534","LU0640476718.USD","LU1366192091.USD","SIVBQ","LU1201861165.SGD","LU0683600562.USD","LU1363072403.SGD","LU0787776722.HKD","LU2133065610.SGD","LU0980610538.SGD","LU0310800965.SGD","PIPR","LU1162221912.USD","LU0256863902.USD","IE00B7SZLL34.SGD","LU0234572021.USD","LU1880398554.USD","BK4504","LU1201861249.SGD","LU1280957306.USD","LU1668664300.SGD","LU2129689605.HKD","LU1883839398.USD"],"gpt_icon":1},{"id":"2505278743","title":"BUZZ-Warner Bros Discovery rises after MoffettNathanson upgrades to 'buy'","url":"https://stock-news.laohu8.com/highlight/detail?id=2505278743","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505278743?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:41","pubTimestamp":1737466874,"startTime":"0","endTime":"0","summary":"BUZZ-Warner Bros Discovery rises after MoffettNathanson upgrades to 'buy'** Media and entertainment company Warner Bros Discovery's shares WBD.O rise 2.2% to $9.74 premarket** Brokerage MoffettNathanson said on Tuesday it is upgrading WBD from 'neutral' to 'buy'** In 2025, WBD is in a more stable financial position due to recent agreements with affiliates such as cable companies, brokerage says** Company's streaming service Max is still growing, and it has overcome some challenges facing its movie studio — MoffettNathanson** Brokerage says improved finances will allow WBD to reduce debt and improve investor perception** WBD management could face pressures from investors to make big changes, including M&A deals. This could lead to a lot of deals and negotiations — MoffettNathanson** Thirteen of 30 brokerages rate the stock \"buy\" or higher, 16 \"hold\" and 1 \"sell\" or lower; their median PT is $12.00 — LSEG** In 2024, WBD lost ~9.1%, outperformed by sector peers such as Netflix NFLX.O, Wal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nL3N3OH16I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIVBQ","DIS","NFLX","FOXA","WBD"],"gpt_icon":1},{"id":"2503524664","title":"BUZZ-Brokerages downgrade Intra-Cellular after J&J deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2503524664","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503524664?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:29","pubTimestamp":1736857767,"startTime":"0","endTime":"0","summary":"BUZZ-Brokerages downgrade Intra-Cellular after J&J deal** Johnson & Johnson JNJ.N said on Monday it would buy neurological drug maker Intra-Cellular Therapies ITCI.O for $14.6 billion** Piper Sandler and Leerink Partners downgrade ITCI to \"neutral\" from \"overweight\" and to \"market perform\" from outperform\" respectively; ITCI is flat in premarket trade** Atleast five brokerages revise ratings and PTs for ITCI after the deal, including three downgrades aside from Piper Sandler and Leerink Partners, according to data compiled by LSEG** \"Given JNJ's desire to establish itself as a leader in the CNS space and Caplyta's strong growth potential in neuropsychiatry, we had seen JNJ as an ideal potential acquirer, and see the acquisition price as fair based on our valuation for Caplyta and ITCI's pipeline\"- TD Cowen** J.P.Morgan analysts say the deal highlights strong strategic interest in neuropsych assets and ITCI is a long-term asset with multi-billion dollar revenue potential** Avg rating of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nL4N3OA0RW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITCI","JNJ","PIPR","SIVBQ"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":35,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SIVBQ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-08","symbol":"SIVBQ","reason":null,"defaultRemindTime":1731076200000,"announcedDate":null,"type":"delisting","dateTimestamp":1731042000000},{"market":"US","date":"2023-10-19","symbol":"SIVBQ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1697688000000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SIVBQ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SIVBQ\",market:\"US\",delay:true,,,undefined,":{}}}